DO Mert Kivanc Hit with DEA Prescribing Decision
Published Date: 10/21/2025
Notice
Summary
Dr. Mert Kivanc from Virginia tried to get a DEA registration but was denied because he didn’t have the proper state authority and didn’t follow the hearing rules. His application was rejected, and he lost the chance to appeal after missing deadlines. This means he can’t legally handle controlled substances, and the decision is final.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
State License Required for DEA Registration
If you are a medical practitioner, you must have valid state authority to handle controlled substances in the state where you practice to obtain a DEA registration. The DEA denied Dr. Mert Kivanc’s DEA application (Control No. W22078481C) because his Virginia medical license was listed as "Suspended," and the denial is effective November 20, 2025. Under 21 U.S.C. 824(a)(3), lack of state authority is an independent basis to deny or revoke DEA registration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-19602, The NCUA Staff Draft 2026-2027 Budget
The NCUA shared its draft budget for 2026-2027, affecting credit unions and their members by planning how money will be spent over the next two years. They’re inviting people to speak or send comments before early November, with a big budget hearing on November 6, 2025. This budget sets the stage for how the NCUA supports credit unions while managing costs carefully.
Next: 2025-19605, Competitive Postal Products
The Postal Service wants to update how it describes its Competitive International Registered Mail to match new global mail rules. This affects customers using international registered mail and related package services. If you have thoughts, you’ve got until October 24, 2025, to share them—so don’t miss out!